The drug development process can be incredibly costly, especially for small and mid-sized biopharma companies that rely heavily on external funding in order to progress through the stages to commercialization. These companies are also heavily reliant on the facilities and knowledge of contract development and manufacturing organizations (CDMOs) due to their smaller workforces and the high costs of acquiring these attributes in-house. Any spend on outsourcing partnerships must therefore be used as efficiently as possible.
